爱康科技(002610.SZ):爱康实业及其一致行动人已合计减持4868万股
格隆汇11月27日丨爱康科技(002610.SZ)公布,2019年11月27日,公司收到爱康投资发来的《股份减持计划实施完成的告知函》,爱康投资已完成减持计划,通过集中竞价交易方式减持数量合计为2034万股,占公司总股本的0.45%。在此之前,控股股东江苏爱康实业集团有限公司(“爱康实业”)于2019年11月14日、11月15日分别通过大宗交易方式减持了1638万股、1196万股,合计2834万股,占公司总股本的0.63%。至此,爱康实业及其一致行动人爱康投资合计减持公司股份4868万股,占公司总股本的1.08%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.